CGAS and Parkinson disease: Importantly, a number of cGAS inhibitors and STING inhibitors have demonstrated brain permeability as a hurdle requirement for future PD treatment, suggesting that these therapeutic agents could hold promise in reaching the neuronal environment and limit the type-I IFN-mediated inflammation in PD (Decout et al., 2021).